Drug Overview

Copper Cu 64 ATSM is an advanced investigational radiopharmaceutical used in cancer imaging and, increasingly, in targeted cancer treatment. Unlike traditional chemotherapy drugs that circulate throughout the entire body, this compound is engineered to seek out a very specific and dangerous feature of tumors: low oxygen levels, also known as hypoxia. This precision makes it one of the most scientifically promising agents in modern nuclear oncology.

The drug is built from two components working together. The first is Copper-64, a radioactive isotope of copper with a half-life of approximately 12.7 hours. This half-life is long enough to allow meaningful imaging and therapeutic activity, yet short enough to limit prolonged radiation exposure to the patient. The second component is ATSM, which stands for diacetyl-bis(N4-methylthiosemicarbazone), a small organic molecule that acts as a carrier, selectively delivering the radioactive copper into oxygen-deprived tumor cells. Together, they form a compound with both diagnostic and therapeutic capabilities, placing Copper Cu 64 ATSM firmly in the exciting and rapidly growing field of theranostics.

Key Details:

Generic Name: Copper Cu 64 ATSM (Copper (64Cu) diacetyl-bis(N4-methylthiosemicarbazone))
US Brand Names: None currently approved. It remains an investigational agent with no commercially marketed brand name in the United States.
Drug Class: Radiopharmaceutical / Theranostic Agent / Hypoxia-Targeting PET Imaging and Therapeutic Agent
Route of Administration: Intravenous (IV) injection
FDA Approval Status: Investigational. Not yet FDA-approved for routine clinical use. It is being actively studied under approved clinical trial protocols and investigational new drug (IND) applications.

What Is It and How Does It Work? (Mechanism of Action)

Hypoxic tumor cells are among the most dangerous in oncology. They resist radiation and chemotherapy and are strongly linked to cancer spread and poor outcomes. Copper Cu 64 ATSM exploits the unique chemistry of these oxygen-deprived zones.

Highlighted Feature: Copper Cu 64 ATSM is both a Targeted Therapy and a Smart Diagnostic Agent — a true theranostic compound capable of simultaneously imaging and treating hypoxic tumors.

Systemic Distribution: Being lipophilic, the compound passively diffuses through cell membranes without requiring surface receptors or transport proteins.

Redox-Sensitive Trapping: Inside cells, copper exists as Cu(II) and is briefly reduced to Cu(I). In healthy, oxygenated cells, oxygen re-oxidizes Cu(I) back to Cu(II) and the compound washes out harmlessly. In hypoxic tumor cells, re-oxidation cannot occur. Cu(I) remains trapped, ATSM breaks down, and free Copper-64 binds irreversibly to intracellular proteins.

Dual Radiation Function: Trapped Copper-64 emits positrons for PET imaging and beta-minus particles and Auger electrons that cause direct DNA double-strand breaks within the cancer cell. Because hypoxic cells have impaired DNA repair, they are especially vulnerable, leading to cell death via apoptosis and mitotic catastrophe.

FDA Approved Clinical Indications

Copper Cu 64 ATSM does not currently hold FDA approval for routine clinical practice. All indications listed below reflect its active investigation in authorized clinical trials.

Oncological Uses (In Clinical Trials):

Glioblastoma Multiforme (Brain Cancer): Imaging and potential targeted radiotherapy of hypoxic tumor cores that resist conventional treatment.
Head and Neck Squamous Cell Carcinoma: Hypoxia mapping to personalize radiation dose escalation strategies.
Prostate Cancer: Identifying hypoxic, therapy-resistant tumor zones to guide treatment intensification.
Cervical Cancer: Used as a prognostic imaging biomarker, with high uptake correlating to poorer treatment outcomes.
Lung Cancer (NSCLC): Mapping oxygen-deprived tumor regions to predict resistance to radiation and systemic therapies.
Colorectal Cancer: Investigated for its ability to identify hypoxic tumor regions that predict chemotherapy failure.
Recurrent and Refractory Solid Tumors: Explored as a targeted radiotherapeutic option when standard treatments have failed.

Non-Oncological Uses (In Clinical Trials):

Cardiac Ischemia Imaging: Early-stage research into using Cu 64 ATSM to visualize oxygen-deprived heart muscle in cardiovascular disease.
Neurological Hypoxia Mapping: Investigational use in stroke and traumatic brain injury to identify regions of cerebral hypoxia.

Dosage and Administration Protocols

Copper Cu 64 ATSM is prepared and administered exclusively in certified nuclear medicine facilities under the supervision of a licensed nuclear medicine physician or radiopharmacist. Dosing protocols may vary between clinical trial sites.

Treatment Detail	Protocol Specification
Standard Imaging Dose	Approximately 370–740 MBq (10–20 mCi); site-specific protocols may vary
Standard Therapeutic Dose	Under active investigation; determined by treating nuclear medicine physician
Route	Intravenous (IV) bolus injection
Frequency	Single dose per imaging or treatment session
Infusion Time	Rapid bolus, typically completed within 1–2 minutes
PET Scan Timing	Imaging typically begins 15–60 minutes post-injection
Renal Dose Adjustment	No standard adjustment currently established; individualized assessment by physician required
Hepatic Dose Adjustment	No standard adjustment currently established; case-by-case clinical evaluation recommended
Preparation Requirements	Must be synthesized in a GMP-certified radiopharmacy under strict radiation containment conditions

Clinical Efficacy and Research Results

Research conducted between 2020 and 2025 has significantly advanced the understanding of Copper Cu 64 ATSM as both an imaging biomarker and a therapeutic agent in hypoxic cancers.

Superior Imaging Performance: Comparative imaging studies have consistently demonstrated that Copper Cu 64 ATSM provides higher tumor-to-background contrast ratios than older hypoxia tracers such as 18F-FMISO. The 12.7-hour half-life of Copper-64 allows for flexible scan timing, enabling delayed imaging that further improves the signal-to-noise ratio and gives clinicians a more accurate picture of the true hypoxic tumor volume.

Prognostic Value in Cervical and Head and Neck Cancers: Multiple clinical investigations have confirmed that patients whose tumors show high Cu 64 ATSM uptake on PET imaging tend to have significantly worse outcomes following standard chemoradiation therapy compared to patients with low uptake. This predictive power positions Cu 64 ATSM as a valuable tool for risk-stratifying patients and identifying those who need treatment escalation before therapy even begins.

Therapeutic Efficacy in Glioblastoma: Emerging clinical trial data from studies examining Cu 64 ATSM as a therapeutic agent in glioblastoma patients have shown encouraging signals of tumor response and disease stabilization in patient populations who had exhausted standard treatment options. While large-scale survival data is still maturing, early results support continued investigation of its therapeutic potential.

Theranostic Pairing and Dosimetry: Researchers are actively using Copper Cu 64 ATSM imaging scans to calculate precise radiation dosimetry for patients being considered for Copper Cu 67 ATSM radiotherapy. This paired approach allows oncologists to predict how much therapeutic radiation a tumor will receive before committing to treatment, enabling a fully personalized and image-guided treatment plan that minimizes exposure to surrounding healthy tissues.

Safety Profile and Side Effects

Black Box Warning: No FDA Black Box Warning currently exists for this investigational agent.

Common Side Effects (>10%):

Injection Site Reactions: Mild pain, redness, warmth, or bruising at the IV site
Transient Fatigue: Mild tiredness related to the procedure rather than direct drug toxicity

Serious Adverse Events (Rare):

Hypersensitivity Reactions: Ranging from mild flushing and urticaria to rare anaphylaxis
Radiation-Related Organ Exposure: Kidneys and liver require dosimetry monitoring at therapeutic doses
Nephrotoxicity Risk: Renal function monitoring recommended for repeated or therapeutic dosing

Management Strategies:

Apply a cool compress to the injection site for bruising or inflammation
Stop IV immediately for allergic reactions; administer antihistamines, corticosteroids, or epinephrine as indicated
Encourage aggressive oral hydration before and after the procedure to support renal clearance
Perform organ dosimetry assessments before therapeutic use to confirm safe exposure thresholds

Research Areas

Immunotherapy Synergy: Hypoxia drives PD-L1 upregulation, shielding tumors from immune attack. Researchers are investigating Cu 64 ATSM PET as a predictive biomarker for checkpoint inhibitor response, with combination strategies pairing hypoxia-targeted radiotherapy with anti-PD-1 or anti-CTLA-4 agents under active study.

Stem Cell Monitoring: Early research explores Cu-ATSM compounds for non-invasively tracking bone marrow engraftment following hematopoietic stem cell transplants, leveraging the tracer’s accumulation in rapidly dividing cells under hypoxic conditions.

Radiosensitizer Combinations: Trial designs are combining Cu 64 ATSM with hypoxia-modifying radiosensitizer drugs — using imaging to locate resistant zones, sensitizers to increase vulnerability, and Cu 64 ATSM therapeutically to maximize tumor cell destruction.

Patient Management and Practical Recommendations

Pre-Treatment Tests to Be Performed:

Pregnancy Test: Mandatory negative serum test within seven days before the procedure
Renal Function Panel: Creatinine and eGFR to confirm safe radiotracer clearance
Baseline Imaging: Prior CT or MRI for anatomical correlation with PET findings
Medication Review: Full disclosure of current medications that may affect copper metabolism

Precautions During Treatment:

Complete stillness required during PET imaging (30–90 minutes) to prevent motion artifacts
Minimize close contact with pregnant women and children under five for the remainder of the day post-procedure
Nursing mothers must consult their physician regarding breastfeeding interruption duration
All procedures conducted in licensed nuclear medicine facilities with full radiation safety infrastructure

Do’s and Don’ts:

DO:

Drink generous amounts of water before and after the scan
Empty your bladder frequently after the procedure
Follow all fasting and dietary instructions from your nuclear medicine team
Disclose all allergies and prior reactions to contrast or nuclear medicine agents

DON’T:

Do not bring pregnant family members or young children to your appointment
Do not exercise vigorously for 24 hours before the scan
Do not breastfeed until cleared by your physician
Do not take copper or zinc supplements without consulting your care team

Legal Disclaimer

This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Copper Cu 64 ATSM is an investigational agent not approved by the FDA for routine clinical use. It is available exclusively through authorized clinical trials under qualified medical supervision. Consult a licensed oncologist or nuclear medicine physician for all healthcare decisions.